BOSENTAN AND PROTEASE INHIBITORS
Ritonavir inhibits the metabolism of bosentan and increases its levels 2-fold.
The manufacturer says that dosage adjustments are not necessary. However, they note that in patients with low levels of CYP2C9 greater increases may occur. Monitoring is therefore advisable as it is unlikely that CYP2C9 phenotype will be known.
The manufacturer says that dosage adjustments are not necessary. However, they note that in patients with low levels of CYP2C9 greater increases may occur. Monitoring is therefore advisable as it is unlikely that CYP2C9 phenotype will be known.